Нафамостат мезилата (Nafamostat mesylate)
Международное непатентованное наименование
Нафамостат мезилата (Nafamostat mesylate)
Торговое наименование
-
Производитель, страна
-
Лекарственная форма
-
Механизм действия
Nafamostat is a serine protease inhibitor and short-acting anti-coagulant. To gain entry into cells, the SARS-CoV-2 virus requires spike protein binding to the angiotensin-converting enzyme 2 (ACE2) and activation of the protease TMPRSS2. Nafamostat can inhibit TMPRSS2 protease function and is thus thought to be able to prevent viral entry into cells.
Публикации COVID-19
Antimicrob Agents Chemother. 2020 Apr 20;AAC.00754-20. DOI: 10.1128/AAC.00754-20.
J Thromb Haemost. 2020 Apr 17. DOI: 10.1111/jth.14858.
Клинические исследования
1.
Название протокола
RAndomized Clinical Trial in COvid19 Patients to Assess the Efficacy of the Transmembrane Protease Serine 2 (TMPRSS2) Inhibitor NAfamostat (RACONA Study)
Дата начала и окончания КИ
April 2020 - December 2021
Название организации, проводящей КИ
University Hospital Padova
Страны
Italy
Фаза
II-III
Кол-во пациентов
256